Aardvark Therapeutics Investors Face October Deadline in Fraud Suit

The litigation, spearheaded by the Rosen Law Firm, targets losses sustained by those who purchased Aardvark common stock via the company’s February 2025 initial public offering or on the open market through May 14, 2026. Plaintiffs contend that the company’s registration statement and subsequent public disclosures obscured critical flaws in the safety profile of ARD-101, ultimately inflating the drug's regulatory and commercial outlook. When these details surfaced, the complaint claims, share prices dropped and investors incurred damages.

Investors holding losses exceeding $100,000 are currently being scouted to represent the class, though participation does not require serving as a lead plaintiff. Those wishing to join the action can contact attorney Phillip Kim to discuss potential recovery options. As the case has not yet been certified as a class action, investors remain free to select their own counsel or opt to stay on the sidelines for the time being. The Rosen Law Firm, which has previously secured substantial settlements in similar litigation, advises that the deadline for filing a motion to serve as lead plaintiff is strictly set for October 13, 2026.